AN2 Therapeutics has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $70,000,000.00 in Post-IPO Equity.
According to filings with the U.S. Securities and Exchange Commission, AN2 Therapeutics is raising $70,000,000.00 in new funding. About AN2 Therapeutics: AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California. Our mission is to develop therapeutics to treat rare, chronic, and serious infectious diseases in areas of high unmet medical need. As leaders in the field of antimicrobials, we also have both an obligation and a strong desire to combine our drug discovery and development expertise with resources available from public and private organizations to address high unmet needs in global health.
To learn more about AN2 Therapeutics, visit http://www.an2therapeutics.com/
Contact:
Joseph Zakrzewski, Chairman
650-331-9090
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.